Immune Responses to Varicella-Zoster Virus Vaccines

Overview

Journal Curr Top Microbiol Immunol

Specialties Allergy & Immunology
Microbiology

Date 2022 Feb 1

PMID 35102438

Authors

Myron J Levin

Adriana Weinberg

Affiliations

Soon will be listed here.

Abstract

The live attenuated varicella vaccine is intended to mimic the tempo and nature of the humoral and cell-mediated immune responses to varicella infection. To date, two doses of varicella vaccine administered in childhood have been very effective in generating varicella-zoster virus (VZV) immune responses that prevent natural infection for at least several decades. After primary infection, the infecting VZV establishes latency in sensory and cranial nerve ganglia with the potential to reactivate and cause herpes zoster. Although, the immune responses developed during varicella are important for preventing herpes zoster they wane with increasing age (immune senescence) or with the advent of immune suppression. Protection can be restored by increasing cell-mediated immune responses with two doses of an adjuvanted recombinant VZV glycoprotein E vaccine that stimulates both VZV-and gE-specific immunity. This vaccine provides ~85-90% protection against herpes zoster for 7-8 years (to date).

Citing Articles

Truncated VZV gE Induces High-Titer Neutralizing Antibodies in Mice.

Wu J, Li H, Yuan Y, Wang R, Shi T, Li Z Vaccines (Basel). 2024; 12(10).

PMID: 39460306 PMC: 11510871. DOI: 10.3390/vaccines12101139.

The impact of the implementation of the two-dose varicella vaccine immunization strategy in Quzhou: A retrospective birth cohort study.

Wen T, Fang Q, Fu C, Zheng C, Pan J, Zheng B Hum Vaccin Immunother. 2024; 20(1):2408847.

PMID: 39344170 PMC: 11445883. DOI: 10.1080/21645515.2024.2408847.

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.

Ulaszewska M, Merelie S, Sebastian S, Lambe T Hum Vaccin Immunother. 2023; 19(1):2175558.

PMID: 36785938 PMC: 10026912. DOI: 10.1080/21645515.2023.2175558.

Rational Design of a Skin- and Neuro-Attenuated Live Varicella Vaccine: A Review and Future Perspectives.

Wang W, Pan D, Cheng T, Zhu H Viruses. 2022; 14(5).

PMID: 35632591 PMC: 9144592. DOI: 10.3390/v14050848.

References

Amanna I, Carlson N, Slifka M . Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007; 357(19):1903-15. DOI: 10.1056/NEJMoa066092. View

Arbeter A, Starr S, Plotkin S . Varicella vaccine studies in healthy children and adults. Pediatrics. 1986; 78(4 Pt 2):748-56. View

Arvin A, Pollard R, Rasmussen L, Merigan T . Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest. 1980; 65(4):869-78. PMC: 434474. DOI: 10.1172/JCI109739. View

Arvin A, Koropchak C, Wittek A . Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis. 1983; 148(2):200-5. DOI: 10.1093/infdis/148.2.200. View

Asada H . VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine. 2019; 37(44):6776-6781. DOI: 10.1016/j.vaccine.2019.09.031. View

Asano Y, Hiroishi Y, Itakura N, Hirose S, Kajita Y, Nagai T . Immunoglobulin subclass antibodies to varicella-zoster virus. Pediatrics. 1987; 80(6):933-6. View

Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M . Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994; 94(4 Pt 1):524-6. View

Baba K, Yabuuchi H, Takahashi M, Ogra P . Immunologic and epidemiologic aspects of varicella infection acquired during infancy and early childhood. J Pediatr. 1982; 100(6):881-5. DOI: 10.1016/s0022-3476(82)80505-2. View

Baba K, Yabuuchi H, Takahashi M, Gershon A, Ogra P . Seroepidemiologic behavior of varicella zoster virus infection in a semiclosed community after introduction of VZV vaccine. J Pediatr. 1984; 105(5):712-6. DOI: 10.1016/s0022-3476(84)80288-7. View

10.

Berkowitz E, Moyle G, Stellbrink H, Schurmann D, Kegg S, Stoll M . Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2014; 211(8):1279-87. PMC: 4371767. DOI: 10.1093/infdis/jiu606. View

11.

Bernstein H, Rothstein E, Watson B, Reisinger K, Blatter M, Wellman C . Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics. 1993; 92(6):833-7. View

12.

Beura L, Fares-Frederickson N, Steinert E, Scott M, Thompson E, Fraser K . CD4 resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J Exp Med. 2019; 216(5):1214-1229. PMC: 6504216. DOI: 10.1084/jem.20181365. View

13.

Bianchi F, Tafuri S, Larocca A, Germinario C, Stefanizzi P . Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study. BMC Infect Dis. 2021; 21(1):475. PMC: 8152326. DOI: 10.1186/s12879-021-06180-x. View

14.

Black S, Ray P, Shinefield H, Saddier P, Nikas A . Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis. 2008; 197 Suppl 2:S139-42. DOI: 10.1086/522124. View

15.

Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra P . Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis. 1982; 146(2):260-5. DOI: 10.1093/infdis/146.2.260. View

16.

Carbone F, Belz G, Heath W . Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004; 25(12):655-8. DOI: 10.1016/j.it.2004.09.013. View

17.

Chaves S, Gargiullo P, Zhang J, Civen R, Guris D, Mascola L . Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007; 356(11):1121-9. DOI: 10.1056/NEJMoa064040. View

18.

Chaves S, Zhang J, Civen R, Watson B, Carbajal T, Perella D . Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis. 2008; 197 Suppl 2:S127-31. DOI: 10.1086/522150. View

19.

Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek J, Richardus J . Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014; 32(15):1745-53. DOI: 10.1016/j.vaccine.2014.01.019. View

20.

Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus J, Plassmann G . Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2015; 34(6):863-8. DOI: 10.1016/j.vaccine.2015.09.073. View